<DOC>
	<DOCNO>NCT01628913</DOCNO>
	<brief_summary>This multicenter , open label , randomize phase II study evaluate efficacy safety BEZ235 compare everolimus patient advance , low intermediate grade pancreatic neuroendocrine tumor ( pNET ) .</brief_summary>
	<brief_title>Efficacy Safety BEZ235 Compared Everolimus Patients With Advanced Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>Patients advance ( unresectable metastatic ) , low intermediate grade ( histologically confirm well moderately differentiate ) pancreatic neuroendocrine tumor ( pNET ) randomize either BEZ235 everolimus . The study plan include 140 patient , 70 patient BEZ235 treatment group 70 patient everolimus treatment group . An interim analysis conduct 62 randomized patient . The study terminate BEZ235 treatment demonstrate progression free survival advantage everolimus treatment .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Advanced histologically confirm well differentiate pancreatic neuroendocrine tumor Progressive disease within last 12 month Measurable disease per RECIST Version 1.0 determine multiphase MRI triphasic CT Prior treatment mTOR PI3K inhibitor Patients 2 prior systemic treatment regimens Previous cytotoxic chemotherapy , target therapy , biotherapy within last 4 week Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>PNET</keyword>
	<keyword>BEZ235</keyword>
	<keyword>Everolimus</keyword>
</DOC>